Severe Human Influenza Infections in Thailand: Oseltamivir Treatment and Risk Factors for Fatal Outcome

Wanna Hanshaoworakul¹, James Mark Simmerman²*, Ubolrat Narueponjirakul³, Wiwan Sanasuttipun², Vivek Shinde³, Suchada Kaewchana², Darin Areechokechai¹, Jens Levy², Kumnuan Ungchusak¹

1 Bureau of Epidemiology, Thailand Ministry of Public Health, Nonthaburi, Thailand, 2 International Emerging Infections Program, Thailand MOPH – U. S. CDC Collaboration, Ministry of Public Health, Nonthaburi, Thailand, 3 Influenza Division, U. S. Centers for Disease Control, Atlanta, Georgia, United States of America

Abstract

**Background:** Influenza is often not recognized as an important cause of severe or fatal disease in tropical and subtropical countries in Southeast Asia. The extent to which Oseltamivir treatment may protect against a fatal outcome in severe influenza infections is not known. Thailand’s National Avian Influenza Surveillance (NAIS) system affords a unique opportunity to describe the epidemiology of laboratory-confirmed severe and fatal human influenza infections.

**Methodology/Principal Findings:** During January 2004 through December 2006, 11,641 notifications to the NAIS were investigated in 73 of 76 Thai provinces. Clinical and demographic data and respiratory swab specimens were collected and tested by PCR for influenza. Using the NAIS database, we identified all patients with laboratory confirmed influenza (A/H3N2, A/H1N1 and Type B) infection. A retrospective medical record review was conducted on all fatal cases with laboratory confirmed influenza and from a sample of hospitalized cases in 28 provinces. The association of underlying risk factors, Oseltamivir treatment and risk of a fatal outcome were examined. Human influenza infections were identified in 2,075 (18%) cases. Twenty-two (1%) deaths occurred including seven deaths in children less than ten years of age. Thirty-five percent of hospitalized human influenza infections had chest X-ray confirmed pneumonia. Current or former smoking; advanced age, hypertension and underlying cardiovascular, pulmonary or endocrine disease were associated with a fatal outcome from human influenza infection. Treatment with Oseltamivir was statistically associated with survival with a crude OR of .11 (95% CI: 0.04–0.30) and .13 (95% CI: 0.04–0.40) after controlling for age.

**Conclusions:** Severe and fatal human influenza infections were commonly identified in the NAIS designed to identify avian A/H5N1 cases. Treatment with Oseltamivir is associated with survival in hospitalized human influenza pneumonia patients.

Introduction

Influenza is a vaccine preventable viral respiratory infection and an important cause of morbidity and mortality in temperate climates, especially among the elderly and the very young [1,2]. In the US, high quality data on the burden of severe and fatal influenza infection has supported policies to expand vaccination programs [3,4]. However in tropical and subtropical climates comparatively little information on disease burden is available, especially data describing severe influenza infections that result in hospitalization or death [5]. The non-specific symptoms of influenza infection and the lack of routine laboratory diagnostic testing in most hospitals significantly limits case ascertainment and reporting. In the absence of data on severe and fatal human influenza infections, clinicians and the general public tend to regard such severe infections as rare. The public health impact of this perception can be significant as influenza antiviral medications and vaccines are available but poorly utilized in many countries in East and Southeast Asia [6]. Recently, research from Hong Kong and Singapore using large mortality databases has suggested that influenza-associated mortality rates are similar to those documented in the United States [7–9]. In less economically developed countries in East and Southeast Asia, such research is hindered by the lack of robust mortality registries and hospital admission databases. Information on influenza disease burden is essential for policy makers considering investment in control programs.

Outbreaks of avian influenza A/H5N1 virus occurred in poultry in Thailand in late 2003 with human H5N1 cases first identified in early 2004 [10]. In response the Thailand Ministry of Public Health (MOPH) established the National Avian Influenza Surveillance (NAIS) system in 2004. The system’s mandate was the identification and prompt investigation of suspected human AI infections in all provinces in all healthcare facilities nationwide [11]. Under NAIS patients presenting with fever and respiratory...
Methods

This research was carried out with approval from and in compliance with the standards of the ethical review committees of the Thailand Ministry of Public Health and the United States Centers for Disease Control and Prevention. During January 2004 through December 2006, the NAIS system recorded 11,641 cases requiring investigation for suspected H5N1 infection reported from 73 of the 76 Thai provinces. All fatal human influenza cases (A/H1N1, A/H3N2, or B) and non-fatal cases hospitalized for two or more days were characterized as severe and eligible for on-site medical record review. Human influenza-associated deaths were patients reported by the NAIS with RT-PCR confirmed influenza infection who died while in the hospital.

We selected the 28 provinces where at least one H5N1 case or human influenza death had been detected by the NAIS. In these 28 provinces, the NAIS recorded 1,488 human influenza infections. We selected all 22 fatal human influenza cases for medical record review. Due to logistical and resource considerations, we sampled a subset of the remaining 1,466 non-fatal human influenza cases using an approach designed to insure that non-fatal cases came from the same population as the fatal cases.

(Figure 1) First, we visited all hospitals where a fatal human influenza case had been admitted. In most cases, these patients had been transferred between 2 or 3 hospitals as their clinical course deteriorated. We then attempted to review all nonfatal human influenza cases from these hospitals. In a few cases the hospital clerical staff was not able to locate all of the medical records. Finally, we visited other small rural, district hospitals located in the same provinces which had also reported non-fatal human influenza cases to the NAIS and attempted to review all available records.

Hospitals were contacted in advance and asked to prepare the medical records for review. A standardized 8-page data collection form was used to collect detailed epidemiological and clinical data including underlying illnesses, smoking and HIV status. Two trained study staff jointly conducted each medical record review. Data were entered into a Microsoft Access database. We conducted post data entry validation of all data fields to assure that the electronic record was identical to the paper medical record review form. We examined the crude, unadjusted relationship of individual demographic, epidemiologic and clinical characteristics in relation to risk of death from human influenza. We used multivariable logistic regression to control for age and estimate adjusted odds ratios of a fatal outcome among hospitalized patients with human influenza infection. Specifically, we compared the 22 fatal human influenza cases with the 423 nonfatal human influenza cases with respect to antiviral treatment and underlying conditions (cardiovascular, hypertension, pulmonary, endocrine disorders, renal disease, neurological disorders, chronic gastrointestinal disease, cancer, and hematological disorders).

Insufficient numbers of subjects were observed to have gastrointestinal disease, cancer, hematological disorders, neurological disorders, renal disease, and underlying conditions (cardiovascular, hypertension, pulmonary, endocrine disorders, renal disease, neurological disorders, chronic gastrointestinal disease, cancer, and hematological disorders).

Results

In 2004 the NAIS recorded 2,846 case investigations including 106 deaths nationwide. In 2005 there were 3,199 investigations and 158 deaths while in 2006 there were 5,596 investigations with 177 deaths. In this population of 11,641 persons, 2,075 (18%) laboratory-confirmed human influenza infections and 22 influenza-associated deaths were identified. Human influenza infections were identified in 73 of the 76 Thai provinces while H5N1 infections were localized to the central and northern regions where most commercial poultry production is located. (Figure 2) In total, we reviewed medical records from 445 human influenza cases admitted to 93 hospitals in 28 Thai provinces. Information on comorbidities was missing on only three individuals, one of which was a fatality. The mean age of sampled cases was 22 years (median 13) and 57% were male. Very young children and the elderly were underrepresented in the study sample compared to other populations under active pneumonia surveillance in Thailand [13,14]. In 2004, subtype A/H1N1 accounted for 36%, A/H3N2 for 38% and Influenza type B accounted for 27% of all infections. In 2005, 50% of human influenza infections were due to A/H3N2 and 43% were due to Influenza B, while the A/H1N1 subtype caused 79% of infections in 2006. (Table 1)

Influenza A/H3N2 caused 8 deaths, subtype A/H1N1 caused 7 deaths and type B caused 7 deaths. Seven (32%) of deaths occurred in children less than 10 years of age, 5 (23%) in patients aged 10–49 years and 10 (45%) of deaths occurred in patients 50 years of age or older. Fifteen (71%) fatal cases had at least one underlying illness. The most frequently documented underlying illness was hypertension [6], followed by cardiovascular disease [4], pulmonary disease [4] and endocrine disorders [4]. Twenty-one (95%) of the fatal cases were diagnosed with a lower respiratory tract infection [LRTI]. The median time from onset of illness until death was 6.5 days (mean 10.7, range 1–68 days). Five (22%) patients with fatal infections had bacterial co-infections reported including 2 cases with Burkholderia pseudomallei, 2 cases with

Influenza and Oseltamivir
Pseudomonas aeruginosa and Staphylococcus aureus coinfection. Among the 423 nonfatal human influenza infections, 340 (80%) were diagnosed with an LRTI. The median duration of illness was 5 days (1–22 days) and the median length of hospital stay was 3 days (range 1–21). There were 150 (35%) chest X-ray confirmed pneumonia cases and 3 of these required endotracheal intubation and intensive care. Among those with a diagnosis of LRTI, 41 (27%) were children 0–5 years while 10 (7%) cases were ≥60 years of age.

The age distribution of sampled cases was slightly older than the non-sampled cases but the gender distribution was similar. (Table 2) Compared to nonfatal cases, cases with a fatal outcome were more likely to have an underlying cardiovascular disease, hypertension, chronic pulmonary disease, and endocrine disorders although only hypertension remained significant after adjustment for age. (Table 3) Death was associated with female gender but this did not reach statistical significance. Previous or current smoking was significantly associated with a fatal outcome but this did not reach statistical significance after controlling for age. Death was associated with advanced age and the 10–19 year age group experienced the fewest fatal cases.

Sixty-three percent of patients were treated with Oseltamivir in 2004, 64% in 2005 and 77% in 2006 (p = .01). Overall, 5 (1.5%) of 318 patients treated with Oseltamivir died compared with 17 (5%) fatal outcomes among 131 patients who did not receive treatment. Antiviral treatment with Oseltamivir was statistically associated with survival with a crude OR with Oseltamivir treatment of .11 (95%CI: 0.04–0.30) and .13 (95%CI: 0.04–0.40) after controlling for age. Oseltamivir was also associated with survival when controlling for the potential confounding variables cardiovascular disease (OR 0.13; 95% CI 0.04–0.38) and hypertension (OR 0.14; 95% CI 0.04–0.44) (data not shown). The mean time from onset of

![Figure 1. Sample selection process.](doi:10.1371/journal.pone.0006051.g001)
Figure 2. Geographic distribution of human influenza cases.
doi:10.1371/journal.pone.0006051.g002
symptoms to initiation of Oseltamivir treatment in the five fatal cases was 4 days (median 4, range 2–7) compared to 2.62 days (median 2, range 0–13) in the 303 surviving patients. Two of the 5 fatal cases who received Oseltamivir treatment died within 2 days of hospital admission.

**Discussion**

In response to concerns regarding A/H5N1 and the raised pandemic threat, Thailand’s NAIS system was rapidly established with a high-quality laboratory diagnostic system that enabled the country to quickly identify a small number of human AI cases among thousands of suspected infections [12]. While each new case of AI received global media attention, the NAIS system identified approximately 80 times as many human influenza infections. More deaths resulted from these infections than from H5N1 (22 versus 17). The surveillance population under the NAIS system was restricted mainly to persons with acute respiratory illness who had a recent history of exposure to sick or dying poultry. In this limited population of 11,641 persons, 2,075 cases of human influenza were identified. Twenty-two deaths were identified that would have otherwise gone unrecognized by the existing passive surveillance system for human influenza. In contrast to the NAIS, between 1999 and 2003 the Thailand national routine passive surveillance system reported only 3 deaths due to human influenza infection. During 2004–2006, a single influenza-associated death was reported through routine passive surveillance in the Thai population of 65 million persons [15]. This under-ascertainment can be explained by the lack of laboratory diagnostic capacity for influenza in nearly all public hospitals and to a common misperception among Thai clinicians that influenza is neither common nor severe.

The NAIS case definition included exposure to sick or dying poultry and consequently very young children and the elderly were underrepresented in our sample. As these age groups are at increased risk for serious complications, the NAIS would not have captured many severe and fatal human influenza infections. Our sampling strategy involved sampling non-fatal cases from the same provinces where fatal human influenza cases (or H5N1 cases) had been reported to best approximate the population from which fatal cases arise. This approach resulted in some small though statistically significant differences in the age structure between sampled and non-sampled cases. Potential variability in the age distribution of the population that each hospital serves could explain these differences.

We observed a statistically significant survival benefit associated with Oseltamivir treatment among patients hospitalized with influenza. This potentially important finding should be interpreted with caution. Although Oseltamivir has been shown to reduce symptom duration, complications and hospitalization among adult outpatients as well as decrease lower respiratory tract infections in observational studies [16–20], evidence of a survival benefit from Oseltamivir treatment for human influenza infection has been infrequently reported [21]. Our small, retrospective, observational study has limitations with respect to establishing causality and we

---

**Table 1. Human influenza cases and deaths reported by National Avian Influenza Surveillance.**

|         | Reported Cases (%) | Reviewed | Deaths† | Reported Cases (%) | Reviewed | Deaths | Reported Cases (%) | Reviewed | Deaths |
|---------|--------------------|----------|---------|-------------------|----------|--------|-------------------|----------|--------|
| A/H1    | 104 (36)           | 27 (40%) | 1       | 40 (8)            | 14 (10%) | 1      | 981 (79)          | 178 (74%) | 5      |
| A/H3    | 110 (38)           | 28 (42%) | 1       | 264 (50)          | 87 (63%) | 5      | 108 (9)           | 28 (12%)  | 2      |
| Type B  | 78 (27)            | 12 (17%) | 1       | 230 (43)          | 37 (27%) | 3      | 160 (13)          | 34 (14%)  | 3      |
| Total   | 292                | 67       | 3       | 534               | 138      | 9      | 1249              | 240      | 10     |

†All deaths also reviewed.

doi:10.1371/journal.pone.0006051.t001

**Table 2. Age and gender distribution of sampled cases compared to all cases reported to NAIS in 28 provinces.**

| Variables | Sampled Cases (#, %) | All Other NAIS Cases (#, %) | Total in 28 Provinces |
|-----------|----------------------|-----------------------------|-----------------------|
| **Age**   |                      |                             |                       |
| 0–4       | 81 (18)              | 182 (17)                    | 263                   |
| 5–9       | 98 (22)              | 285 (27)                    | 383                   |
| 10–19     | 101 (23)             | 238 (23)                    | 339                   |
| 20–59     | 135 (30)             | 302 (29)                    | 437                   |
| 60+       | 30 (7)               | 36 (3)                      | 66                    |
| **Gender**|                      |                             |                       |
| Male      | 259 (58)             | 574 (55)                    | 833 (56)              |
| Female    | 186 (42)             | 469 (45)                    | 655 (44)              |
| **Total** | 445                  | 1043                        | 1488                  |

Chi square for Age Distribution P = 0.02

Chi square for Gender Distribution P = 0.26

doi:10.1371/journal.pone.0006051.t002
lacked additional information such as functional status and severity of illness scores which may have confounded or biased our results. However, the strength and significance of these data indicate a survival benefit from Oseltamivir treatment in hospitalized influenza patients. More research is needed to verify these findings which could influence pneumonia case management approaches as well as strategies for antiviral use during a pandemic.

Outside of Singapore and Hong Kong, no epidemiological studies of human influenza-associated mortality have been published in Southeast Asia [5]. The 22 deaths we uncovered probably represent only a small fraction of human influenza-associated mortality in Thailand during 2004–2007 given the narrowly defined criteria for testing based on risk factors for H5N1. Although data on influenza-associated mortality in Thailand are not available, a few recent studies provide insight into the contribution of influenza to inpatient pneumonia and outpatient febrile respiratory illness in Thailand [22,23]. While the precise figure varies from year to year, approximately 8–10% of hospitalized pneumonia cases in Thailand are attributed to human influenza infection [24,25]. In our study, 35% of all hospitalized

| Table 3. Factors associated with a fatal outcome. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Outcome         | Unadjusted OR   | 95% CI          | Age Adjusted OR |
|                 | Fatal (%)       | Non-Fatal (%)   |                 |                 |
| Year            |                 |                 |                 |                 |
| 2004            | 3 (14%)         | 64 (15%)        | 1.08 0.29–4.03  | 1.21 0.20–5.09  |
| 2005            | 9 (41%)         | 129 (31%)       | 1.60 0.64–3.80  | 1.66 0.57–4.81  |
| 2006            | 10 (45%)        | 230 (54%)       | 1 ref           | 1 ref           |
|                 |                 |                 | chi-sq 0.59     |                 |
| Antiviral Treatment|                |                 |                 |                 |
| No Oseltamivir  | 17 (77%)        | 113 (27%)       | 1 ref           | 1 ref           |
| Oseltamivir     | 5 (23%)         | 310 (73%)       | 0.11 0.04–0.30  | 0.13 0.04–0.40  |
|                 |                 |                 | chi-sq <0.0001  |                 |
| Comorbidities   |                 |                 |                 |                 |
| No Cardiovascular disease | 17 (81%) | 408 (97%) | 1 ref           | 1 ref           |
| Cardiovascular disease | 4 (19%) | 13 (3%) | 7.38 2.18–25.04 | 4.04 1.08–15.11 |
|                 |                 |                 | chi-sq 0.0002   |                 |
| No Hypertension | 15 (71%)        | 407 (97%)       | 1 ref           | 1 ref           |
| Hypertension    | 6 (29%)         | 14 (3%)         | 11.63 3.92–34.46 | 4.67 1.03–20.85 |
|                 |                 |                 | chi-sq <0.0001  |                 |
| No Chronic pulmonary disease | 17 (81%) | 401 (95%) | 1 ref           | 1 ref           |
| Chronic pulmonary disease | 4 (19%) | 20 (5%) | 4.72 1.45–15.32 | 3.11 0.64–11.76 |
|                 |                 |                 | chi-sq 0.0048   |                 |
| No Endocrine disorder | 17 (81%) | 414 (98%) | 1 ref           | 1 ref           |
| Endocrine disorder | 4 (19%) | 7 (2%) | 13.92 3.71–52.13 | 5.01 0.84–26.56 |
|                 |                 |                 | chi-sq <0.0001  |                 |
| Gender          |                 |                 |                 |                 |
| Male            | 10 (45%)        | 249 (59%)       | 1 ref           | 1 ref           |
| Female          | 12 (55%)        | 174 (41%)       | 1.72 0.73–4.06  | 1.7 0.63–4.55   |
|                 |                 |                 | chi-sq 0.21     |                 |
| Tobacco         |                 |                 |                 |                 |
| Never           | 15(75%)         | 385(93%)        | 1 ref           | 1 ref           |
| Current         | 3(15%)          | 18(4%)          | 4.3 1.1–16.1    | 1.93 0.28–10.01 |
| Former          | 2(10%)          | 10(2%)          | 5.1 1.0–25.5    | 2.08 0.17–14.28 |
|                 |                 |                 | chi-sq 0.006    |                 |
| Age             |                 |                 |                 |                 |
| 0 to 9          | 7 (32%)         | 172 (41%)       | 4.1 0.5–33.6    | -               |
| 10 to 19        | 1 (5%)          | 100 (24%)       | 1 ref           | -               |
| 20–49           | 4 (18%)         | 99 (23%)        | 4.0 0.4–36.8    | -               |
| 50 plus         | 10 (45%)        | 52 (12%)        | 19.2 2.4–154.4  | -               |
|                 |                 |                 | chi-sq <0.0001  |                 |

*Age Adjusted ORs calculated using Exact Logistic Regression methods.
doi:10.1371/journal.pone.0006051.t003
influenza cases had been diagnosed with chest X-ray confirmed pneumonia. Studies from other regional countries report that 11–26% of outpatients with febrile respiratory illness have influenza virus infections [5].

In conclusion, our findings suggest that the national passive surveillance system substantially underreports the burden of severe and fatal human influenza infection in Thailand and that treatment with Oseltamivir may provide a survival benefit in these patients. The elderly, smokers and persons with underlying comorbidities with human influenza infection are at increased risk of a fatal outcome. Further research on influenza-associated mortality and Oseltamivir treatment using national hospital discharge, mortality and influenza surveillance databases is needed to inform influenza control policies, guide clinical management and support pandemic preparedness planning.

Acknowledgments
The authors wish to thank Ms. Prane Thawatsupa, Ms. Malinee Jitrakarnpit, Dr. Ruengreung Kitphati, and Dr. Pathom Sawanpanyalert, of the Thailand National Institute of Health, for their work on laboratory confirmation for all cases reported to the NAsIS, We sincerely thank the staff of the Surveillance and Response unit at the Bureau of Epidemiology for their support in case identification and data collection. Dr. Alicia Frery, Dr. Joseph Bresee and Dr. Carolyn Bridges of the US Centers for Disease Control and Prevention, Influenza Division, are gratefully acknowledged for their careful review of this manuscript. Finally, we would like to thank the Southeast Asia Office of the US CDC and the Thailand Ministry of Public Health for financially supporting this research.

Author Contributions
Conceived and designed the experiments: JS. Performed the experiments: WH UN VS SK DA. Analyzed the data: WH JS VS JL. Wrote the paper: WH JS. Senior epidemiologist and supervisor, responsible for all scientific output of the program: KU.

References
1. Thompson WW, Shay DK, Weintraub E, Bramer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. Jama 289: 179–186.
2. Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, et al. (2006) Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 24: 102–108.
3. Nichol KL, Nordfin JD, Nelson DB, Mullody JP, Hak E (2007) Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357: 1373–1381.
4. Fiore AE, Shay DK, Broder KS, Ickander JK, Uyeki TM, et al. (2008) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity & Mortality Weekly Report Recommendations & Reports 57.
5. Simmerman J, Uyeki T (2008) The burden of influenza in East and South-East Asia: a review of the English language literature. Influenza and Other Respiratory Viruses 2: 81–92.
6. (2003) The macro-epidemiology of influenza vaccination in 56 countries, 1997–2003. Vaccine 23: 5133–5143.
7. Wong CM, Chan KP, Hedley AJ, Peiris JS (2004) Influenza-associated mortality in Hong Kong. Clin Infect Dis 39: 1611–1617.
8. Li CK, Choi BC, TW W (2006) Influenza-related deaths and hospitalizations in Hong Kong: a subtropical area. Public Health 120: 517–524; Epub 2006 May 19.
9. Chow A, Ma S, Ling AE, Chew SK (2006) Influenza-associated deaths in tropical Singapore. Emerg Infect Dis 12: 114–121.
10. Tamin T, Chaitoosreth P, Songserm T, Chaiwing A, Stegeman A (2005) Highly Pathogenic Avian Influenza H5N1, Thailand, 2004. Emerg Infect Dis 11: 1664–1672.
11. Chunsuttiwat S (2008) Response to avian influenza and preparedness for pandemic influenza: Thailand's experience. Respirology 13 Suppl 1: S36–40.
12. Kitphati R, Apisarnthanarak A, Chittaganpitch M, Tawatsuphab P, Anuvait W, et al. (2008) A nationally coordinated laboratory system for human avian influenza A (H5N1) in Thailand: program design, analysis, and evaluation. Clin Infect Dis 46: 1394–1400.
13. Olsen SJ, Laosiritaworn Y, Siasirirattakan S, Chunsuttiwat S, Dowell SF (2006) The incidence of pneumonia in rural Thailand. Int J Infect Dis 10: 439–445.
14. Prapasiri P, Jirapipituk S, Kesawan A, Chumnum T, Baggett HC, et al. (2006) Epidemiology of radiographically-confirmed and bacteremic pneumonia in rural Thailand. Southeast Asian J Trop Med Public Health 37: 706–718.
15. Epidemiology Bo (2007) Annual epidemiology surveillance report 2007. Bangkok: Thailand Ministry of Public Health, pp 477.
16. Hayden FG, Favia AT (2006) Antiviral management of seasonal and pandemic influenza. J Infect Dis 194 Suppl 2: S119–126.
17. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, et al. (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163: 1667–1672.
18. Nordstrom BL, Sung I, Suter P, Sznee P (2005) Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 21: 761–768.
19. Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ (2004) Health outcomes among patients receiving oseltamivir. Pharmacoeconomic Drug Saf 13: 227–238.
20. Lee N, Chan PK, Choi KW, Lui G, Wong B, et al. (2007) Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 12: 501–508.
21. McGregor A, Green KA, Plevnesi A, Shigaye A, Siddiqi N, et al. (2007) Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 45: 1560–1575.
22. Katz MA, Tharmaphornphiphat P, Chantra S, Dowell SF, Uyeki T, et al. (2007) Who gets hospitalized for influenza pneumonia in Thailand? Implications for vaccine policy. Vaccine 25: 3827–3833.
23. Simmerman JM, Chittaganpitch M, Erdman D, Sawatwong P, Uyeki TM, et al. (2005) Field Performance and New Uses for Rapid Influenza Testing in Thailand. Journal of Clinical Microbiology.
24. Simmerman JM, Lerttupanong J, Dowell SF, Uyeki T, Olsen SJ, et al. (2006) The cost of influenza in Thailand. Vaccine 24: 4417–4420.
25. Suntarattiwong P, Sarn-norka C, Thongtipaa P, Thawatsuphab P, Kitphati R, et al. (2008) Influenza-associated hospitalization in urban Thai children. Influenza and Other Respiratory Viruses 1: 177–182.